Fennec Pharmaceuticals Announces Positive PEDMARK® Clinical Data at ASCO, Expanding Use to AYA and Adult Patients
FENC sits 76% above its 52-week low of $5.65.
Summary
Fennec Pharmaceuticals announced new research at the ASCO Annual Meeting, detailing positive clinical data for PEDMARK® in adolescent, young adult, and adult patient populations, expanding its potential utility beyond its current pediatric indication.
Key Events · Product Development and Regulatory · FENC
-
Positive Clinical Data for PEDMARK®
New research presented at the ASCO Annual Meeting details PEDMARK®'s efficacy in reducing cisplatin-induced ototoxicity in adolescent, young adult, and adult patient populations.
-
Phase 2/3 Trial Met Primary Endpoint
Detailed results from the investigator-initiated Phase 2/3 STS-J01 clinical trial in Japan showed a significant reduction in hearing loss (16-24% vs. 56-63% historically) in 3-18 year-old patients.
-
Expanded Clinical Utility
Real-world evidence supports the feasible incorporation of PEDMARK® into AYA and adult oncology workflows without compromising cisplatin's antitumor activity, including in head and neck cancer patients.
-
Addressing Unmet Need
The studies highlight PEDMARK®'s potential to impact patient care more broadly by addressing permanent hearing loss, a major survivorship issue in oncology.
Analysis · FENC · Life Sciences
This filing provides significant positive clinical updates for Fennec's key product, PEDMARK®. The detailed results from four independent studies, including a Phase 2/3 trial in Japan, demonstrate PEDMARK®'s efficacy in reducing cisplatin-induced hearing loss in broader patient groups (AYA and adults). This expands the potential market and clinical utility of the drug, reinforcing its value proposition and addressing a critical unmet need in oncology survivorship.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 34.7% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FENC was trading at $9.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $344.9M. The 52-week trading range was $5.65 to $10.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.